| schema:articleBody
| - PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today launched the first cell painting kit as part of its new portfolio of PhenoVue? cellular imaging reagents. This new range of reagents leverages PerkinElmer's expertise in cellular imaging and high-content screening and works alongside the Company's microplates, automation, software and industry-leading high-content screening instruments. With this entire screening workflow, researchers can better understand disease and develop more pinpointed therapies and drugs to treat them. Cell painting is a powerful application of high-content screening technology which combines cell and computational biology to study the effects of perturbagens such as chemical compounds, drugs or genes on the behavior of cells. Cells are "painted" by labelling cellular compartments with different fluorescent bioprobes to enable those areas to be quantitatively profiled. However, preparing reagents from scratch can be incredibly time consuming. Helping to address this challenge, the PhenoVue? cell painting kit provides convenience and simplicity through a ready-to-use format and is part of a new range of reagents that also includes fluorescent organelle staining probes and dye-labelled secondary antibodies. These reagents are validated for high-content screening applications to reduce customers' assay development time. For example, customers can use these reagents with PerkinElmer's CellCarrier? Ultra microplates, the PerkinElmer Opera Phenix® Plus high-content screening system, Operetta CLS? high-content analysis system and Harmony® high-content analysis software. "Researchers are using high-content screening and cell painting to make extraordinary discoveries that will help drive more innovative drugs and therapies," said Alan Fletcher, Vice President and GM of Life Sciences, PerkinElmer. "With the addition of our new PhenoVue? cellular imaging reagents, we now offer a complete suite of high-content screening products and expert services. This will help researchers build more streamlined workflows and enjoy the convenience of working with a single, expert technology provider helping to accelerate discovery." For more information on PerkinElmer's new PhenoVue cellular imaging reagents, please visit www.perkinelmer.com/PhenoVue. About PerkinElmer PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com. View source version on businesswire.com: Contact Adriana Howell +1 765 918 3070 Adriana.howell@perkinelmer.com © 2021 Business Wire, Inc. Disclaimer: This material is not an AFP editorial material, and AFP shall not bear responsibility for the accuracy of its content. In case you have any questions about the content, kindly refer to the contact person/entity mentioned in the text of the release.
|
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)